Price T Rowe Associates Inc Precigen, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Precigen, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 169,501 shares of PGEN stock, worth $152,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
169,501
Previous 165,152
2.63%
Holding current value
$152,550
Previous $240,000
11.67%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding PGEN
# of Institutions
143Shares Held
144MCall Options Held
292KPut Options Held
53.8K-
Third Security, LLC83.5MShares$75.1 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD18.2MShares$16.4 Million1.57% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$9.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.76MShares$6.08 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$2.79 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $187M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...